Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

BACKGROUND: This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β(2)-agonist (LABA). METHODS: 285 patients with symptomatic asthma, despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohta, Ken, Ichinose, Masakazu, Tohda, Yuji, Engel, Michael, Moroni-Zentgraf, Petra, Kunimitsu, Satoko, Sakamoto, Wataru, Adachi, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404354/
https://www.ncbi.nlm.nih.gov/pubmed/25894430
http://dx.doi.org/10.1371/journal.pone.0124109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404354/
https://www.ncbi.nlm.nih.gov/pubmed/25894430
http://dx.doi.org/10.1371/journal.pone.0124109

Ejemplares similares